aducanumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
aducanumab

GtoPdb Ligand ID: 8325

Synonyms: aducanumab-avwa | Aduhelm® | BART | BIIB-037 | BIIB037

aducanumab is an approved drug (FDA (2021))

Compound class: Antibody

Comment: Aducanumab is a fully human IgG1-kappa monoclonal antibody directed against the amyloid beta (Aβ) found in the amyloid plaques in the brain tissue of patients with Alzheimer's disease (AD).
Peptide sequences and structural information about this antibody are available from its IMGT/mAb-DB record. A patent search reveals Biogen Idec's patent submission WO2014089500 [2].

References
1. Biogen. Q3 2019 Financial Results and Business Update. Accessed on 03/12/2019. Modified on 03/12/2019. investors.biogen.com, http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c
2. Bussiere T, Weinreb PH, Engber T, Rhodes K, Arndt J, Qian F, Dunstan RW, Patel S. (2014) A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES. Patent number: WO2014089500. Assignee: Biogen Idec International Neuroscience Gmbh. Priority date: 07/12/2012. Publication date: 12/06/2014.
3. Cho S, Gaamouch FE, Upadhyay S, Nada H, Kuncewicz K, Gabr MT. (2025) As48, a First-in-Class Dual-Function TREM2 Modulator: Receptor Activation and Shedding Inhibition. bioRxiv,. [PMID:40909719]
4. Cho S, Kaur B, Lam K, Gaamouch FE, Kuncewicz K, Doering NP, Wolber G, Gabr MT. (2025) Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis. bioRxiv,. [PMID:40909477]
5. Cho S, Szalai TV, El Gaamouch F, Bajusz D, Keserű GM, Gabr M. (2025) AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity. bioRxiv,. [PMID:41000669]
6. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. (2021) Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther, 13 (1): 98. [PMID:33971962]
7. Curtis D, Joseph S, Alzheimer’s Disease Neuroimaging Initiative. (2025) Analysis of whole genome sequence data shows association of Alzheimer's disease with rare coding variants in ABCA7, PSEN1, SORL1 and TREM2. J Neurogenet, 39 (4): 95-104. [PMID:40990081]
8. Howard R, Liu KY. (2020) Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol, 16 (2): 63-64. [PMID:31784690]
9. Ji KY, Kim SM, Yee SM, Kim MJ, Ban YJ, Kim EM, Lee EH, Choi HR, Yun H, Lee CW et al.. (2021) Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells-2 (TREM2). FASEB J, 35 (4): e21479. [PMID:33710680]
10. Liu KY, Schneider LS, Howard R. (2021) The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry, 8 (11): 1013-1016. [PMID:34087114]
11. Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M et al.. (2024) Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimers Res Ther, 16 (1): 235. [PMID:39444037]
12. Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, Gao J, Budda B, Park LQ, Gupta R et al.. (2026) The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nat Med, 32 (5): 1708-1716. [PMID:41787076]
13. Saeb D, Lietzke EE, Fuchs DI, Aldrich EC, Bruce KD, Sprenger KG. (2025) The flexible stalk domain of sTREM2 modulates its interactions with brain-based phospholipids. Elife, 13. [PMID:40928206]
14. Schlepckow K, Morenas-Rodríguez E, Hong S, Haass C. (2023) Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease. Lancet Neurol, 22 (11): 1048-1060. [PMID:37863592]
15. Schneider L. (2019) A resurrection of aducanumab for Alzheimer's disease. The Lancet Neurology, In Press, Corrected Proof. DOI: 10.1016/S1474-4422(19)30480-6
16. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et al.. (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537 (7618): 50-6. [PMID:27582220]
17. Sharma C, Mazumder A. (2025) From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease. Cent Nerv Syst Agents Med Chem, [Epub ahead of print]. [PMID:40993929]
18. Tsui JSM, Au DM, Uhm H, Wong WW, Lo RMN, Jiang Y, Ip FCF, Mok KY, Wong HY, Kwok TCY et al.. (2025) The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune-related processes. Alzheimers Dement, 21 (9): e70586. [PMID:40960087]
19. Yang H, Kim D, Yang Y, Bagyinszky E, An SSA. (2025) TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting. Int J Mol Sci, 26 (15). [PMID:40806186]
20. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. (2016) TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron, 91 (2): 328-40. [PMID:27477018]
21. Yuan S, El Gaamouch F, Cho S, Kuncewicz K, Nada H, Gabr MT. (2025) Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement. ACS Med Chem Lett, 16 (8): 1634-1640. [PMID:40832531]
22. Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M et al.. (2018) TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. Neuron, 97 (5): 1023-1031.e7. [PMID:29518356]

References

1. Biogen.
Q3 2019 Financial Results and Business Update.
Accessed on 03/12/2019. Modified on 03/12/2019. investors.biogen.com, http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c

2. Bussiere T, Weinreb PH, Engber T, Rhodes K, Arndt J, Qian F, Dunstan RW, Patel S. (2014)
A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES.
Patent number: WO2014089500. Assignee: Biogen Idec International Neuroscience Gmbh. Priority date: 07/12/2012. Publication date: 12/06/2014.

3. Cho S, Gaamouch FE, Upadhyay S, Nada H, Kuncewicz K, Gabr MT. (2025)
As48, a First-in-Class Dual-Function TREM2 Modulator: Receptor Activation and Shedding Inhibition.
bioRxiv,. [PMID:40909719]

4. Cho S, Kaur B, Lam K, Gaamouch FE, Kuncewicz K, Doering NP, Wolber G, Gabr MT. (2025)
Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis.
bioRxiv,. [PMID:40909477]

5. Cho S, Szalai TV, El Gaamouch F, Bajusz D, Keserű GM, Gabr M. (2025)
AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity.
bioRxiv,. [PMID:41000669]

6. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. (2021)
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
Alzheimers Res Ther, 13 (1): 98. [PMID:33971962]

7. Curtis D, Joseph S, Alzheimer’s Disease Neuroimaging Initiative. (2025)
Analysis of whole genome sequence data shows association of Alzheimer's disease with rare coding variants in ABCA7, PSEN1, SORL1 and TREM2.
J Neurogenet, 39 (4): 95-104. [PMID:40990081]

8. Howard R, Liu KY. (2020)
Questions EMERGE as Biogen claims aducanumab turnaround.
Nat Rev Neurol, 16 (2): 63-64. [PMID:31784690]

9. Ji KY, Kim SM, Yee SM, Kim MJ, Ban YJ, Kim EM, Lee EH, Choi HR, Yun H, Lee CW et al.. (2021)
Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells-2 (TREM2).
FASEB J, 35 (4): e21479. [PMID:33710680]

10. Liu KY, Schneider LS, Howard R. (2021)
The need to show minimum clinically important differences in Alzheimer's disease trials.
Lancet Psychiatry, 8 (11): 1013-1016. [PMID:34087114]

11. Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M et al.. (2024)
Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.
Alzheimers Res Ther, 16 (1): 235. [PMID:39444037]

12. Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, Gao J, Budda B, Park LQ, Gupta R et al.. (2026)
The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.
Nat Med, 32 (5): 1708-1716. [PMID:41787076]

13. Saeb D, Lietzke EE, Fuchs DI, Aldrich EC, Bruce KD, Sprenger KG. (2025)
The flexible stalk domain of sTREM2 modulates its interactions with brain-based phospholipids.
Elife, 13. [PMID:40928206]

14. Schlepckow K, Morenas-Rodríguez E, Hong S, Haass C. (2023)
Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
Lancet Neurol, 22 (11): 1048-1060. [PMID:37863592]

15. Schneider L. (2019)
A resurrection of aducanumab for Alzheimer's disease.
The Lancet Neurology, In Press, Corrected Proof. DOI: 10.1016/S1474-4422(19)30480-6

16. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et al.. (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Nature, 537 (7618): 50-6. [PMID:27582220]

17. Sharma C, Mazumder A. (2025)
From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease.
Cent Nerv Syst Agents Med Chem, [Epub ahead of print]. [PMID:40993929]

18. Tsui JSM, Au DM, Uhm H, Wong WW, Lo RMN, Jiang Y, Ip FCF, Mok KY, Wong HY, Kwok TCY et al.. (2025)
The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune-related processes.
Alzheimers Dement, 21 (9): e70586. [PMID:40960087]

19. Yang H, Kim D, Yang Y, Bagyinszky E, An SSA. (2025)
TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting.
Int J Mol Sci, 26 (15). [PMID:40806186]

20. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. (2016)
TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.
Neuron, 91 (2): 328-40. [PMID:27477018]

21. Yuan S, El Gaamouch F, Cho S, Kuncewicz K, Nada H, Gabr MT. (2025)
Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement.
ACS Med Chem Lett, 16 (8): 1634-1640. [PMID:40832531]

22. Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M et al.. (2018)
TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.
Neuron, 97 (5): 1023-1031.e7. [PMID:29518356]